CN108164574A - 小花清风藤中的一种化合物及其制备方法与应用 - Google Patents
小花清风藤中的一种化合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN108164574A CN108164574A CN201711441167.1A CN201711441167A CN108164574A CN 108164574 A CN108164574 A CN 108164574A CN 201711441167 A CN201711441167 A CN 201711441167A CN 108164574 A CN108164574 A CN 108164574A
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- alcohol
- extraction
- fractions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 241000081623 Sabia parviflora Species 0.000 title claims abstract description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 41
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims abstract description 14
- 230000008818 liver damage Effects 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 9
- 239000002253 acid Substances 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 6
- 229930182478 glucoside Natural products 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- 235000019441 ethanol Nutrition 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000010828 elution Methods 0.000 claims description 10
- 239000011347 resin Substances 0.000 claims description 10
- 229920005989 resin Polymers 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- HNVRRHSXBLFLIG-UHFFFAOYSA-N 3-hydroxy-3-methylbut-1-ene Chemical class CC(C)(O)C=C HNVRRHSXBLFLIG-UHFFFAOYSA-N 0.000 claims description 4
- QNXSIUBBGPHDDE-UHFFFAOYSA-N alpha-indanone Natural products C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
- 238000001641 gel filtration chromatography Methods 0.000 claims description 3
- 230000014759 maintenance of location Effects 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- CYTYCFOTNPOANT-UHFFFAOYSA-N Perchloroethylene Chemical compound ClC(Cl)=C(Cl)Cl CYTYCFOTNPOANT-UHFFFAOYSA-N 0.000 claims description 2
- 238000007803 cold maceration Methods 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000005325 percolation Methods 0.000 claims description 2
- 238000002137 ultrasound extraction Methods 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 230000007246 mechanism Effects 0.000 claims 1
- 239000000741 silica gel Substances 0.000 claims 1
- 229910002027 silica gel Inorganic materials 0.000 claims 1
- 210000005229 liver cell Anatomy 0.000 abstract description 10
- 102000003952 Caspase 3 Human genes 0.000 abstract description 9
- 108090000397 Caspase 3 Proteins 0.000 abstract description 9
- 230000006907 apoptotic process Effects 0.000 abstract description 9
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 abstract description 9
- 238000002474 experimental method Methods 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 4
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical class C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 abstract 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 abstract 1
- 150000008131 glucosides Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 150000002576 ketones Chemical class 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 9
- 208000004930 Fatty Liver Diseases 0.000 description 7
- 208000010706 fatty liver disease Diseases 0.000 description 7
- 206010019708 Hepatic steatosis Diseases 0.000 description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 6
- 231100000240 steatosis hepatitis Toxicity 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- 235000021314 Palmitic acid Nutrition 0.000 description 3
- 208000034189 Sclerosis Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 208000015707 frontal fibrosing alopecia Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- 244000205574 Acorus calamus Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 235000011996 Calamus deerratus Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 241001083952 Sabiaceae Species 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000015337 arteriosclerotic cardiovascular disease Diseases 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 150000001555 benzenes Chemical group 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001425 electrospray ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000000874 microwave-assisted extraction Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940043263 traditional drug Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 三酰甘油(μmol/L protein) | caspase3活力(U/g protein) | MDA(mg/g) |
空白组 | 39.9±4.8 | 2.46±0.33 | 0.89±0.01 |
模型组 | 306.3±54.0 | 5.38±0.64 | 0.54±0.03 |
给药组(低) | 254.8±38.7* | 5.01±0.37* | 0.68±0.02* |
给药组(中) | 231.2±36.5* | 4.54±0.47* | 0.71±0.05* |
给药组(高) | 190.2±50.3* | 4.05±0.54* | 0.82±0.03* |
组别 | 凋亡率% |
空白组 | 0 |
模型组 | 45.2 |
给药组(低) | 34.2* |
给药组(中) | 28.6* |
给药组(高) | 23.9* |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711441167.1A CN108164574B (zh) | 2017-12-27 | 2017-12-27 | 小花清风藤中的一种化合物及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711441167.1A CN108164574B (zh) | 2017-12-27 | 2017-12-27 | 小花清风藤中的一种化合物及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108164574A true CN108164574A (zh) | 2018-06-15 |
CN108164574B CN108164574B (zh) | 2020-02-18 |
Family
ID=62521692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711441167.1A Active CN108164574B (zh) | 2017-12-27 | 2017-12-27 | 小花清风藤中的一种化合物及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108164574B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111925404A (zh) * | 2020-09-09 | 2020-11-13 | 江西中医药大学 | 一种木脂素类化合物的制备方法与应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106631747A (zh) * | 2017-02-08 | 2017-05-10 | 江西本草天工科技有限责任公司 | 一种新的化合物在制备保肝药物或保健品中的应用 |
CN106866609A (zh) * | 2017-02-08 | 2017-06-20 | 江西本草天工科技有限责任公司 | 小花清风藤中一种新化合物的制备方法及应用 |
-
2017
- 2017-12-27 CN CN201711441167.1A patent/CN108164574B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106631747A (zh) * | 2017-02-08 | 2017-05-10 | 江西本草天工科技有限责任公司 | 一种新的化合物在制备保肝药物或保健品中的应用 |
CN106866609A (zh) * | 2017-02-08 | 2017-06-20 | 江西本草天工科技有限责任公司 | 小花清风藤中一种新化合物的制备方法及应用 |
Non-Patent Citations (1)
Title |
---|
HYUNCHEOL OH,等: "Hepatoprotective and free radical scavenging activities of phenolic petrosins and flavonoids isolated from Equisetum arvense", 《JOURNAL OF ETHNOPHARMACOLOGY》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111925404A (zh) * | 2020-09-09 | 2020-11-13 | 江西中医药大学 | 一种木脂素类化合物的制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
CN108164574B (zh) | 2020-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wu et al. | Triterpenoids from Ganoderma lucidum and their potential anti-inflammatory effects | |
Yue et al. | Chemical and biological properties of quinochalcone C-glycosides from the florets of Carthamus tinctorius | |
Ge et al. | Novel caffeoylquinic acid derivatives from Lonicera japonica Thunb. flower buds exert pronounced anti-HBV activities | |
US9950021B2 (en) | Anti-cancer active substance from Antrodia camphorata, method for preparing the same and use thereof | |
CN102058678B (zh) | 一种治疗脂肪肝的药物或保健食品组合物 | |
Liu et al. | An in vivo and in vitro assessment of the anti-inflammatory, antinociceptive, and immunomodulatory activities of Clematis terniflora DC. extract, participation of aurantiamide acetate | |
Shang et al. | Gymnadenia conopsea (L.) R. Br.: a systemic review of the ethnobotany, phytochemistry, and pharmacology of an important Asian folk medicine | |
CN106866609B (zh) | 小花清风藤中一种新化合物的制备方法及应用 | |
Tseng et al. | Effects of three purgative decoctions on inflammatory mediators | |
Tung et al. | Isolation and chemopreventive evaluation of novel naphthoquinone compounds from Alkanna tinctoria | |
CN106631747B (zh) | 一种新的化合物在制备保肝药物或保健品中的应用 | |
US20090318400A1 (en) | Method for inhibiting tumor growth with dehydrosulphurenic acid extracted from antrodia cinnamomea | |
Han et al. | Hepatoprotective glucosyloxybenzyl 2-hydroxy-2-isobutylsuccinates from Pleione yunnanensis | |
Luo et al. | Astramalabaricosides A–T, highly oxygenated malabaricane triterpenoids with migratory inhibitory activity from Astragalus membranaceus var. mongholicus | |
CN109810154B (zh) | 小花清风藤生物碱类化合物、制备方法、应用及其组合物 | |
CN108164574A (zh) | 小花清风藤中的一种化合物及其制备方法与应用 | |
CN108084009A (zh) | 小花清风藤中的一种化合物及其制备方法与应用 | |
CN105837595A (zh) | 阿替洛尔的药物组合物及其在生物医药中的应用 | |
CN113512017B (zh) | 一种莱菔叶千里光中的化合物及其制备方法与应用 | |
CN108904490A (zh) | 赶黄草中二氢黄酮衍生物在制备抗肝细胞脂肪变性的药物中的应用 | |
CN111925404B (zh) | 一种木脂素类化合物的制备方法与应用 | |
Zhang et al. | Screening and identifying hepatotoxic components in Polygoni multiflori Radix and Polygoni multiflori Radix Praeparata | |
CN102838570B (zh) | 脉络宁酯及其制备方法和用途 | |
CN104926891B (zh) | 竹叶青酒中的生物活性成分及药物用途 | |
KR20110087397A (ko) | 이소디히드로오로글로신을 유효성분으로 함유하는 암 질환의 예방 및 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20191210 Address after: 330004 Jiangxi city of Nanchang province Wanli District Hing Wan Road No. 818 Applicant after: JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE Applicant after: Bencao Tian'gong Science & Tech. Co., Ltd., Jiangxi Address before: 330006 No. 56 Yangming Road, East Lake District, Jiangxi, Nanchang Applicant before: Bencao Tian'gong Science & Tech. Co., Ltd., Jiangxi Applicant before: JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE |
|
GR01 | Patent grant | ||
GR01 | Patent grant |